SCHEMBL12439072

SCHEMBL12439072

CNc1cnc(Cl)cc1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNA4 P43681 1/20 0.36
KDM4E B2RXH2 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
GAA P10253 1/20 0.33
LRRK2 Q5S007 1/20 0.33
KAT2B Q92831 1/20 0.32
BRD9 Q9H8M2 1/20 0.32
TNIK Q9UKE5 1/20 0.32
KCNQ3 O43525 1/20 0.32
KCNQ2 O43526 1/20 0.32
NNMT P40261 2/20 0.31
DGAT1 O75907 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C19 P33261 1/20 0.31
HIF1A Q16665 1/20 0.31
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
ABL1 P00519 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16187963 0.83 ALDH1A1 (0.36) ALDH1A1CHRNB2CHRNA4KDM4ESMN1; SMN2
SCHEMBL17671197 0.81 ALDH1A1 (0.35) ALDH1A1CHRNB2CHRNA4KDM4ESMN1; SMN2
SCHEMBL20772360 0.81 ALDH1A1 (0.35) ALDH1A1CHRNB2CHRNA4KDM4ESMN1; SMN2
SCHEMBL12395925 0.81 ALDH1A1 (0.35) ALDH1A1CHRNB2CHRNA4KDM4ESMN1; SMN2
SCHEMBL16879136 0.80 NNMT (0.34) ALDH1A1KDM4ESMN1; SMN2GAALRRK2
SCHEMBL23845599 0.78 CHRNB2 (0.36) ALDH1A1CHRNB2CHRNA4KDM4ESMN1; SMN2
SCHEMBL1746425 0.77 UHRF1 (0.48) NNMT
SCHEMBL15173500 0.77 TDP1 (0.35) ALDH1A1KDM4EGAAKAT2BBRD9
SCHEMBL31257580 0.77 TDP1 (0.35) ALDH1A1KDM4EGAAKAT2BBRD9
SCHEMBL1872686 0.77 KAT2B (0.32) KAT2BBRD9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024105364-A1 HETEROCYCLIC INHIBITORS OF CDC-LIKE KINASES CURADEV PHARMA LTD (GB) 2024-05-23 WO disclosed
EP-3730487-A1 AZETIDINE DERIVATIVES AS FXR (NR1H4) MODULATORS Gilead Sciences, Inc. (US) 2020-10-28 EP disclosed
US-10011568-B2 Cyclohexyl pyridine derivative KISSEI PHARMACEUTICAL CO., LTD. (JP) 2018-07-03 US disclosed
US-10011568-B2 Cyclohexyl pyridine derivative KISSEI PHARMACEUTICAL CO., LTD. (JP) 2018-07-03 US disclosed
EP-3067349-B1 CARBOXYMETHYL PIPERIDINE DERIVATIVE KISSEI PHARMACEUTICAL (JP) 2018-02-28 EP disclosed
US-20170298024-A1 CYCLOHEXYL PYRIDINE DERIVATIVE KISSEI PHARMACEUTICAL CO., LTD. (JP) 2017-10-19 US disclosed
US-20170298024-A1 CYCLOHEXYL PYRIDINE DERIVATIVE KISSEI PHARMACEUTICAL CO., LTD. (JP) 2017-10-19 US disclosed
US-9708266-B2 Cyclohexyl pyridine derivative KISSEI PHARMACEUTICAL CO., LTD. (JP) 2017-07-18 US disclosed
US-9708266-B2 Cyclohexyl pyridine derivative KISSEI PHARMACEUTICAL CO., LTD. (JP) 2017-07-18 US disclosed
EP-3141541-A1 CYCLOHEXYL-PYRIDINE DERIVATIVE Kissei Pharmaceutical Co., Ltd. (JP) 2017-03-15 EP disclosed
US-20170057920-A1 CYCLOHEXYL PYRIDINE DERIVATIVE KISSEI PHARMACEUTICAL CO., LTD. (JP) 2017-03-02 US disclosed
US-20170057920-A1 CYCLOHEXYL PYRIDINE DERIVATIVE KISSEI PHARMACEUTICAL CO., LTD. (JP) 2017-03-02 US disclosed
US-20160289206-A1 CARBOXYMETHYL PIPERIDINE DERIVATIVE KISSEI PHARMACEUTICAL CO., LTD. (JP) 2016-10-06 US disclosed
US-20160289206-A1 CARBOXYMETHYL PIPERIDINE DERIVATIVE KISSEI PHARMACEUTICAL CO., LTD. (JP) 2016-10-06 US disclosed
US-8426450-B1 Substituted 4-phenyl pyridines having anti-emetic effect HELSINN HEALTHCARE SA (CH) 2013-04-23 US disclosed
US-8404708-B2 Dual NK1/NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2013-03-26 US disclosed
US-8404708-B2 Dual NK1/NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2013-03-26 US disclosed
US-20110178055-A1 DUAL NK1/NK3 RECEPTOR ANTAGONISTS HOFFMANN TORSTEN 2011-07-21 US disclosed
US-20110178055-A1 DUAL NK1/NK3 RECEPTOR ANTAGONISTS HOFFMANN TORSTEN 2011-07-21 US disclosed
EP-1643998-B1 DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA HOFFMANN LA ROCHE (CH) 2007-08-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178055-A1 DUAL NK1/NK3 RECEPTOR ANTAGONISTS TACR2, TAC3, TACR1 ALDH1A1 1516/4885CHRNB2 801/4885CHRNA4 468/4885
US-20170298024-A1 CYCLOHEXYL PYRIDINE DERIVATIVE CYP3A43, CYP3A5, CYP3A4 ALDH1A1 600/4885CHRNB2 1316/4885CHRNA4 374/4885
US-10011568-B2 Cyclohexyl pyridine derivative CYP3A43, CYP3A5, CYP3A4 ALDH1A1 600/4885CHRNB2 1316/4885CHRNA4 374/4885
US-20160289206-A1 CARBOXYMETHYL PIPERIDINE DERIVATIVE TACR1, CYP3A5, CNR1 ALDH1A1 165/4885CHRNB2 2148/4885CHRNA4 704/4885
US-20170057920-A1 CYCLOHEXYL PYRIDINE DERIVATIVE CYP3A43, CYP3A5, CYP3A4 ALDH1A1 581/4885CHRNB2 1314/4885CHRNA4 373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.